Xeris Biopharma (NASDAQ:XERS) Stock: Insider Steven Pieper Sells 5,000 Shares

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Steven Pieper sold 5,000 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total value of $51,150.00. Following the completion of the sale, the insider owned 1,346,053 shares of the company’s stock, valued at approximately $13,770,122.19. This trade represents a 0.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

• On Thursday, October 1st, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $9.41, for a total transaction of $47,050.00.
• On Tuesday, September 1st, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.50, for a total value of $42,500.00.
• On Wednesday, August 12th, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.50, for a total value of $42,500.00.

Xeris Biopharma Trading Up 1.1%

Shares of NASDAQ:XERS traded up $0.11 during midday trading on Wednesday, reaching $10.46. The company had a trading volume of 3,142,009 shares, compared to its average volume of 2,030,196. The company has a fifty day simple moving average of $9.37 and a two-hundred day simple moving average of $7.54. The firm has a market cap of $1.91 billion, a price-to-earnings ratio of -95.09 and a beta of 0.61. Xeris Biopharma Holdings, Inc. has a 1-year low of $5.25 and a 1-year high of $11.41. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. The company had revenue of $92.10 million for the quarter, compared to analyst estimates of $90.12 million. Research analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current year.

Institutional Trading of Xeris Biopharma

A number of hedge funds have recently made changes to their positions in XERS. StoneX Group Inc. purchased a new position in Xeris Biopharma during the third quarter valued at approximately $142,000. Pictet Asset Management Holding SA increased its stake in Xeris Biopharma by 13.7% in the 3rd quarter. Pictet Asset Management Holding SA now owns 34,107 shares of the company’s stock valued at $326,000 after buying an additional 4,108 shares during the period. AlphaCentric Advisors LLC increased its stake in Xeris Biopharma by 4.2% in the 3rd quarter. AlphaCentric Advisors LLC now owns 48,489 shares of the company’s stock valued at $464,000 after buying an additional 1,940 shares during the period. Commonwealth Equity Services LLC lifted its position in Xeris Biopharma by 3.6% in the 3rd quarter. Commonwealth Equity Services LLC now owns 213,337 shares of the company’s stock worth $2,040,000 after buying an additional 7,482 shares in the last quarter. Finally, Jacksonville Wealth Management LLC lifted its position in Xeris Biopharma by 11.8% in the 3rd quarter. Jacksonville Wealth Management LLC now owns 19,000 shares of the company’s stock worth $182,000 after buying an additional 2,000 shares in the last quarter. 42.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on XERS shares. Leerink Partners boosted their price target on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a report on Thursday, September 10th. Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Wall Street Zen upgraded shares of Xeris Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Finally, Barclays boosted their target price on shares of Xeris Biopharma from $12.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, October 6th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Xeris Biopharma has a consensus rating of “Moderate Buy” and a consensus price target of $13.20.

About Xeris Biopharma

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.